CSL is trading 6.01% up now at $29.79 as investors continued buying after the August 18 FY2026 results, where underlying earnings exceeded expectations.
- Management forecast approximately 5% FY2027 profit growth, above consensus.
- CSL announced a A$1.1 billion share buyback and maintained its dividend, reinforcing confidence in the recovery outlook.
- Follow-through buying remains strong despite weaker broader market and biotech-sector conditions.